Fraunhofer Institute for Cell Therapy and Immunology IZIInnovative medicines, such as gene and cell therapies or mRNA-based vaccines, should be made available to a broad patient population within an affordable healthcare system in the future. To this end, Fraunhofer combines biotechnological and production technology developments in the field of mRNA medicines. We offer a wide range of research services to academic and industrial partners. These range from the screening and functional testing of mRNA and LNP formulations to the development of mRNA-based cell therapies and vaccine candidates, as well as their production processes. For the production of mRNA-LNP complexes, Fraunhofer has developed a modular and adaptable facility that integrates in-line quality controls, is digitally controlled, and is represented as a digital twin. In this way, we support the entire value chain.
Automated production technologies for mRNA-based drugs
On the following pages, you'll find detailed information about our services.